Azidothymidine 복용후 Human Immunodeficiency Virus 감염자의 CD4＋T 림프구수, β₂-Microglobulin 및 p24 항원 변화 = Change of Serum β₂-Microglobulin, p24 Antigen and CD4＋T Lymphocyte in Persons with Human Immunodeficiency Virus Infection after Azidothymidine Treatment

다국어 초록 (Multilingual Abstract)

The effect of azidothymidine (AZT) in 48 HIV-infected patients taking AZT was evaluated by CD4+ T lymphocyte counts, serum β₂-microglobulin (β₂-MG), and p24 antigen levels. The results were also compared with the group without AZT. Annual decrease of CD4+ T lymphocyte counts was 70 cells/μL in group without AZT Tx and 38 cells/μL in group with AZT Tx. Response rate of CD4+ T lymphocyte counts to AZT Tx was 77% within 2 months, 68% within 2 to 6 months, 41% within 6 to 12 months and 31% within 12 to 24 months after AZT Tx. The level of B₂-MG dropped from 2.95±1.45㎎/L at 2.2 months before Tx to 2.87±0.9㎎/L at 2.4 months after Tx, and than increased to 3.05±1.11㎎/L at 7.4±4.4 months after AZT Tx. HIV p24 antigen was detected in 26(14.9%) of 174 persons with HIV infection. p24 antigen level tested within 2 months after AZT Tx decreases in 9(69%) of 13 patients receiving Tx. And p24 antigen level showed significant decrease from 11.2±11.2pg/㎖ to 5.6±3.2pg/㎖ at 1.8±0.8 months after AZT Tx (p<0.01) and then increase to 18.4±18.5pg/㎖ at 6.2±3.2 months after Tx(p<0.01). The data indicate that drug resistance to AZT gradually develops within one year after AZT Tx.